Crinetics Pharmaceuticals Inc

CRNX

Equity

ISIN US22663K1079 / Valor 42455144

NASDAQ (2025-03-28)

USD 34.73-0.49%

Crinetics Pharmaceuticals Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Crinetics Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Leveraging its expertise in endocrine pharmacology, the company aims to address unmet medical needs by developing small molecule drugs that target specific hormonal pathways. Crinetics' lead product candidates include paltusotine, an oral nonpeptide somatostatin receptor agonist for the treatment of acromegaly and neuroendocrine tumors, and CRN04894, an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease and congenital adrenal hyperplasia. The company is headquartered in San Diego, California, and actively collaborates with various research and entrepreneurial organizations to foster innovation in the biotech sector.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-25.8%1Y

82.3%3Y

140%5Y

Performance

52.1%1Y

62.6%3Y

66.7%5Y

Volatility